Multi-drug resistance protein 2 (MRP2) expression, adjuvant tamoxifen therapy, and risk of breast cancer recurrence: a Danish population-based nested case-control study.

CONCLUSIONS: MRP2 expression is neither a predictive marker of tamoxifen effectiveness nor a prognostic marker in breast cancer.
PMID: 30458661 [PubMed - as supplied by publisher]

Source: Acta Oncologica - November 20, 2018 Category: Cancer & Oncology Authors: Hjorth CF, Nielsen AS, Sørensen HT, Lash TL, Damkier P, Hamilton-Dutoit S, Cronin-Fenton D Tags: Acta Oncol Source Type: research